• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A New Vaccine to Battle Covid-19.

作者信息

Haynes Barton F

机构信息

From the Departments of Medicine and Immunology, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.

出版信息

N Engl J Med. 2021 Feb 4;384(5):470-471. doi: 10.1056/NEJMe2035557. Epub 2020 Dec 30.

DOI:10.1056/NEJMe2035557
PMID:33378607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7787216/
Abstract
摘要

相似文献

1
A New Vaccine to Battle Covid-19.一种对抗新冠病毒的新型疫苗。
N Engl J Med. 2021 Feb 4;384(5):470-471. doi: 10.1056/NEJMe2035557. Epub 2020 Dec 30.
2
Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.信使 RNA 新冠病毒 2019 疾病（COVID-19）疫苗对医护人员队列中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性。
Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379. doi: 10.1093/cid/ciab361.
3
Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.在首次发生免疫性血小板减少性紫癜后成功进行mRNA SARS-CoV-2疫苗再次接种。
Platelets. 2022 May 19;33(4):652-653. doi: 10.1080/09537104.2022.2044463. Epub 2022 Feb 28.
4
Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.mRNA 平台在 SARS-CoV-2 疫苗方面的积极方面。
Hum Vaccin Immunother. 2021 Aug 3;17(8):2445-2447. doi: 10.1080/21645515.2021.1900713. Epub 2021 Apr 8.
5
Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.通过推迟mRNA疫苗的第二剂接种来加速2019冠状病毒病（COVID-19）疫苗的推广。
Clin Infect Dis. 2021 Oct 5;73(7):1320-1321. doi: 10.1093/cid/ciab068.
6
How important is the second dose of the COVID-19 mRNA vaccine?新冠病毒mRNA疫苗的第二剂有多重要？
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2537. doi: 10.1016/j.jaip.2021.02.061.
7
Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study.BNT162b2 mRNA新冠疫苗接种后引发的免疫性血栓性血小板减少症：一项病例研究
Thromb Res. 2021 Dec;208:1-3. doi: 10.1016/j.thromres.2021.10.002. Epub 2021 Oct 9.
8
Three doses of mRNA COVID-19 vaccine protects from SARS-CoV-2 infections in Japan.在日本，三剂新冠mRNA疫苗可预防新冠病毒感染。
J Intern Med. 2022 Oct;292(4):687-689. doi: 10.1111/joim.13526. Epub 2022 Jun 3.
9
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
10
US authorization of first COVID vaccine marks new phase in safety monitoring.美国首次批准新冠疫苗标志着安全监测进入新阶段。
Nature. 2020 Dec;588(7838):377-378. doi: 10.1038/d41586-020-03542-4.

引用本文的文献

1
mRNA vaccine development and applications: A special focus on tumors (Review).mRNA 疫苗的开发与应用：特别关注肿瘤（综述）。
Int J Oncol. 2024 Aug;65(2). doi: 10.3892/ijo.2024.5669. Epub 2024 Jul 12.
2
Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development.用于药物/基因递送的脂质纳米颗粒：生产技术概述及其产业化发展中遇到的困难
ACS Mater Au. 2023 Aug 21;3(6):600-619. doi: 10.1021/acsmaterialsau.3c00032. eCollection 2023 Nov 8.
3
COVID-19 emergency: the influence of implicit attitudes, information sources, and individual characteristics on psychological distress, intentions to get vaccinated, and compliance with restrictive rules.新冠疫情紧急情况：内隐态度、信息来源和个体特征对心理困扰、接种疫苗意愿及遵守限制规定的影响
Health Psychol Rep. 2021 Dec 6;10(1):1-12. doi: 10.5114/hpr.2021.111292. eCollection 2022.
4
Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response.应对新冠疫情后的免疫时代：了解新冠长期症状与免疫反应
Life (Basel). 2023 Oct 26;13(11):2121. doi: 10.3390/life13112121.
5
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection.一种拉沙病毒 mRNA 疫苗在豚鼠感染模型中提供保护，但不需要中和抗体。
Nat Commun. 2023 Sep 12;14(1):5603. doi: 10.1038/s41467-023-41376-6.
6
CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.CHO 细胞产生的 RBD-Fc 亚单位疫苗与不同佐剂联合使用可产生针对 SARS-CoV-2 的免疫应答。
PLoS One. 2023 Jul 14;18(7):e0288486. doi: 10.1371/journal.pone.0288486. eCollection 2023.
7
Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III).评估EpiVacCorona肽疫苗预防COVID-19的安全性和预防效果（III期）。
Vaccines (Basel). 2023 May 18;11(5):998. doi: 10.3390/vaccines11050998.
8
In utero delivery of mRNA to the heart, diaphragm and muscle with lipid nanoparticles.利用脂质纳米颗粒在子宫内将信使核糖核酸递送至心脏、膈肌和肌肉。
Bioact Mater. 2023 Feb 17;25:387-398. doi: 10.1016/j.bioactmat.2023.02.011. eCollection 2023 Jul.
9
Review of current vaccine development platform to prevent coronavirus disease.预防冠状病毒病的当前疫苗开发平台综述。
Natl J Maxillofac Surg. 2022 Sep-Dec;13(3):337-346. doi: 10.4103/njms.njms_454_21. Epub 2022 May 26.
10
Pediatric COVID-19 Vaccination: A Description of Adverse Events or Reactions Reported in Kansans Aged 6 to 17.儿科新冠疫苗接种：堪萨斯州6至17岁人群报告的不良事件或反应描述
Kans J Med. 2022 Nov 28;15(3):390-393. doi: 10.17161/kjm.vol15.18431. eCollection 2022.

本文引用的文献

1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
SARS-CoV-2 Vaccination - An Ounce (Actually, Much Less) of Prevention.新型冠状病毒2型疫苗接种——一盎司（实际上远少于此）的预防措施。
N Engl J Med. 2020 Dec 31;383(27):2677-2678. doi: 10.1056/NEJMe2034717. Epub 2020 Dec 10.
4
Correlates of protection against SARS-CoV-2 in rhesus macaques.恒河猴中 SARS-CoV-2 保护作用的相关因素。
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
5
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
6
Prospects for a safe COVID-19 vaccine.安全的 COVID-19 疫苗前景。
Sci Transl Med. 2020 Nov 4;12(568). doi: 10.1126/scitranslmed.abe0948. Epub 2020 Oct 19.
7
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.《 老年人中新型冠状病毒 mRNA-1273 疫苗的安全性和免疫原性》
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
8
Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.大流行防范：开发针对 COVID-19 的疫苗和治疗性抗体。
Cell. 2020 Jun 25;181(7):1458-1463. doi: 10.1016/j.cell.2020.05.041. Epub 2020 May 27.
9
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.